Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.
The Company's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Alferon LDO. Ampligen is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases.

Type
Public
HQ
Philadelphia, US
Founded
1990
Size (employees)
32 (est)
Hemispherx BioPharma was founded in 1990 and is headquartered in Philadelphia, US
Report incorrect company information

Hemispherx BioPharma Office Locations

Hemispherx BioPharma has an office in Philadelphia
Philadelphia, US (HQ)
1190 One Penn Center 1617 John F Kennedy Blvd
Philadelphia, US
500 One Penn Center 1617 John F Kennedy Blvd
Show all (2)
Report incorrect company information

Hemispherx BioPharma Financials and Metrics

Hemispherx BioPharma Financials

Hemispherx BioPharma's revenue was reported to be $92 k in FY, 2016 which is a 30.8% decrease from the previous period.
USD

Revenue (Q1, 2018)

56 k

Net income (Q1, 2018)

(2.7 m)

EBIT (Q1, 2018)

(2.6 m)

Market capitalization (18-Jun-2018)

14.2 m

Closing share price (18-Jun-2018)

0.3

Cash (31-Mar-2018)

4 m
Hemispherx BioPharma's current market capitalization is $14.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

150 k197 k133 k92 k

Revenue growth, %

31%(32%)(31%)

General and administrative expense

7.7 m9.1 m7.1 m7.7 m

R&D expense

8.4 m9 m8 m5.1 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018

Revenue

36 k45 k36 k47 k23 k39 k15 k22 k84 k90 k56 k

General and administrative expense

2.5 m2.2 m1.9 m2 m1.7 m2.4 m1.6 m1.6 m1.7 m1.6 m1.6 m

R&D expense

2.3 m1.9 m2.7 m2.4 m2 m1 m900 k1.3 m1.4 m787 k855 k

Operating expense total

4.8 m4.1 m4.6 m4.4 m3.7 m3.5 m2.5 m3 m3.1 m2.7 m2.6 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

803 k2.2 m2.1 m2.4 m

Accounts Receivable

Inventories

399 k335 k

Current Assets

18.6 m16.5 m10.6 m6.9 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018

Cash

2.6 m1.3 m2.9 m1.8 m1.2 m1 m1.5 m4.5 m776 k503 k4 m

Accounts Receivable

41 k42 k29 k

Inventories

626 k

Current Assets

20.5 m17.7 m17.9 m17.1 m14 m9.5 m10.7 m9.3 m5.2 m3.7 m5.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(16.2 m)(17.5 m)(15.2 m)(7.5 m)

Depreciation and Amortization

671 k665 k941 k1.1 m

Inventories

(1.3 m)

Accounts Payable

(617 k)869 k(196 k)(326 k)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(8.8 m)(13 m)(3.4 m)(8.3 m)(12.1 m)(2.2 m)(3.5 m)(6.3 m)(2.8 m)(2.7 m)

Depreciation and Amortization

332 k500 k180 k458 k663 k300 k576 k854 k261 k216 k

Inventories

(480 k)(1 m)(1.3 m)

Accounts Payable

238 k1.2 m236 k189 k97 k182 k178 k(202 k)103 k245 k
USDY, 2018

Financial Leverage

1.6 x
Show all financial metrics
Report incorrect company information